相关实验视频

Updated: Jul 26, 2026

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

超氧化物脱酶亚型的铜伴奏剂作为光线B乳腺癌的预后标志物

Yanping Li¹, Wenfei Du¹, Rui Yang¹

¹Precision Medicine Laboratory for Chronic Non-communicable Diseases of Shandong Province, Institute of Precision Medicine, Jining Medical University, Jining, China.

Clinical Medicine Insights. Oncology

|January 8, 2024

概括

超氧化物失突酶 (CCS) 的铜伴奏在光线B乳腺癌中表达很高,与生存率差相关. 乳腺癌CCS显示出作为这种乳腺癌亚型的预后标记物的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

超氧化物脱酶 (CCS) 的铜伴奏对细胞氧化还原平衡至关重要.
乳腺癌细胞中CCS表达的升高促进了增殖和迁移.
乳腺癌的异质性可能与不同的CCS分子亚型有关.

研究的目的:

为了研究乳腺癌中CCS表达模式.
分析CCS表达和临床病理学参数之间的相关性.
为了评估CCS在光线B乳腺癌的预后价值.

主要方法:

使用TNMplot,cBioPortal,HPA,UALCAN,TCGA和bc-GenExMiner数据库进行表达式分析.
评估了与年龄,种族,ER,PR,HER2和BRCA1/2突变状态的相关性.
在光线B患者的生存分析中使用卡普兰-梅尔曲线和考克斯回归.

主要成果:

CCS表达与患者年龄,种族,ER和PR状态相关联.
BRCA1/2突变影响了CCS表达水平.
光线B亚型表现出最高的CCS表达,与较差的存活率相关.
在光线B患者中高CCSmRNA表达预测了不良结果.

结论:

在光线B乳腺癌中,CCS显著表达.
CCS作为光线B乳腺癌的独立预后预测器.
作为B型乳腺癌治疗的治疗标志物,CCS显示出前景.

关键词:

超氧化物脱酶的铜伴侣.TNM 图表图表图表乌尔坎 (UALCAN) 是一个 bc-GenExMiner 的使用方法乳腺癌乳腺癌乳腺癌发光器B的发光器B.

更多相关视频

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...